Anti-Myc target protein 1 MYCT1 Antibody

MYCT1 was initially identified as a novel target of the c-Myc oncogene in myeloid cells. It is a widely expressed nuclear protein whose overexpression can promote apoptosis, alteration of morphology, enhancement of anchorage-independent cell growth, tumorigenic conversion, promotion of genomic instability, and inhibition of hematopoietic differentiation. MYCT1 binds to the promoters of several c-Myc-regulated genes and it has been suggested that the phenotypes seen in MYCT1-overexpressing cells are a result of the deregulation of these genes. RUNX1-ETO, a fusion protein made up of RUNX1 and ETO, is thought to deregulate the proliferation and responsiveness of human hematopoietic progenitor cells downstream of MYCT1.

MYCT1 antibody was raised against a 17 amino acid synthetic peptide near the carboxy terminus of human MYCT1. The immunogen is located within the last 50 amino acids of MYCT1.

May regulate certain MYC target genes, MYC seems to be a direct upstream transcriptional activator. Does not seem to significantly affect growth cell capacity. Overexpression seems to mediate many of the known phenotypic features associated with MYC, including promotion of apoptosis, alteration of morphology, enhancement of anchorage-independent growth, tumorigenic conversion, promotion of genomic instability, and inhibition of hematopoietic differentiation (By similarity) . .

MYCT1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.